NASDAQ, TSX: NVCN
VANCOUVER, Aug. 6, 2018 /CNW/ - Neovasc Inc. ("Neovasc" or
the "Company") (NASDAQ:NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve
replacement technologies, today announced publication of the manuscript, "Safety and efficacy of the Reducer: A multicenter
clinical registry - REDUCE study" in the International Journal of Cardiology, which is available online at: https://doi.org/10.1016/j.ijcard.2018.06.116.
In this published study, the safety and effectiveness of the Neovasc Reducer™ ("Reducer"), a CE-Marked medical device designed
for the treatment of refractory angina, was evaluated using a real-world cohort of 141 patients in three high-volume medical
centers in Milan, Tel Aviv and Antwerp. The researchers aimed to evaluate the efficacy of the Reducer in improving quality of life and
reducing symptoms of angina pectoris in 141 consecutive patients suffering from coronary artery disease and chronic refractory
angina. The safety endpoint of the study was to evaluate the rate of successful Reducer delivery and deployment in the absence of
any device-related events.
The investigator demonstrated that treatment with the Reducer was very safe and significantly reduced the severity of angina
as measured by the Canadian Cardiovascular Society classification ("CCS") (from a mean at baseline of 3.05±0.53 to 1.63±0.98 at
follow-up (p<0.001). Overall, results show that 81% of the patients experienced improvement in their angina severity by at
least one CCS class, and 45% of the patients became free of any limiting angina as they improved by 2 or more grades in their CCS
class. All parameters of quality of life as measured by the Seattle Angina Questionnaire improved significantly (p
<0.001). These benefits translated into a significant reduction in the mean number of anti-ischemic drugs prescribed (2.37±
0.97 vs 2.17±0.95; p= 0.003).
"The publication is another 'real-world,' non-randomized study which demonstrates clinical results in an additional 141
enrolled patients, that are remarkably consistent with the results of the COSIRA randomized sham-controlled clinical trial. This
recent manuscript published in the International Journal of Cardiology is a testament to the benefits of the Reducer as a safe
device, which can provide substantial qualify of life improvements in patients with refractory angina, who do not have other
suitable treatment alternatives," stated Fred Colen, Neovasc's President and Chief Executive
Officer. "We are very pleased to have this data published in such a highly-regarded journal."
About Neovasc Inc.
Neovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing
cardiovascular marketplace. Its products include the Reducer, for the treatment of refractory angina, which is not currently
commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is
currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com.
This news release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995 and applicable Canadian securities laws regarding the future performance and potential benefit of the Reducer
and growth of the cardiovascular marketplace . Words and phrases such as 'potential', "believes," "may", "not yet" and
"will" and similar words or expressions, are intended to identify these forward-looking statements. Forward-looking statements
are based on estimates and assumptions made by the Company in light of its experience and its perception of historical trends,
current conditions and expected future developments, as well as other factors that the Company believes are appropriate in the
circumstances. Many factors and assumptions could cause the Company's actual results, performance or achievements to differ
materially from those expressed or implied by the forward-looking statements, including, without limitation, the substantial
doubt about the Company's ability to continue as a going concern; risks relating to the warrants (the "Warrants") and senior
secured convertible notes (the "Notes") issued pursuant to the November 2017 underwritten public
offering and concurrent private placement (together, the "2017 Financings"), resulting in significant dilution to the Company's
shareholders; risks relating to the Company's need for significant additional future capital and the Company's ability to raise
additional funding; risks relating to cashless exercise and adjustment provisions in the Warrants and Notes issued pursuant to
the 2017 Financings, which could make it more difficult and expensive for the Company to raise additional capital in the future
and result in further dilution to investors; risks relating to the sale of a significant number of common shares of the Company;
risks relating to the exercise of Warrants or conversion of Notes issued pursuant to the 2017 Financings, which may encourage
short sales by third parties; risks relating to the possibility that the Company's common shares may be delisted from the Nasdaq
Capital Market or the Toronto Stock Exchange, which could affect their market price and liquidity; risks relating to the
Company's common share price being volatile; risks relating to the influence of significant shareholders of the Company over the
Company's business operations and share price; risks relating to the Company's significant indebtedness, and its effect on the
Company's financial condition; risks relating to claims by third parties alleging infringement of their intellectual property
rights; risks relating to lawsuits that the Company is subject to, which could divert the Company's resources and result in the
payment of significant damages and other remedies; the Company's ability to establish, maintain and defend intellectual property
rights in the Company's products; risks relating to results from clinical trials of the Company's products, which may be
unfavorable or perceived as unfavorable; the Company's history of losses and significant accumulated deficit; risks associated
with product liability claims, insurance and recalls; risks relating to use of the Company's products in unapproved
circumstances, which could expose the Company to liabilities; risks relating to competition in the medical device industry,
including the risk that one or more of the Company's competitors may develop more effective or more affordable products; risks
relating to the Company's ability to achieve or maintain expected levels of market acceptance for the Company's products, as well
as the Company's ability to successfully build its in-house sales capabilities or secure third-party marketing or distribution
partners; the Company's ability to convince public payors and hospitals to include the Company's products on their approved
products lists; risks relating to new legislation, new regulatory requirements and the efforts of governmental and third-party
payors to contain or reduce the costs of healthcare; risks relating to increased regulation, enforcement and inspections of
participants in the medical device industry, including frequent government investigations into marketing and other business
practices; risks associated with the extensive regulation of the Company's products and trials by governmental authorities, as
well as the cost and time delays associated therewith; risks associated with post-market regulation of the Company's products;
health and safety risks associated with the Company's products and industry; risks associated with the Company's manufacturing
operations, including the regulation of the Company's manufacturing processes by governmental authorities and the availability of
two critical components of the Reducer; risk of animal disease associated with the use of the Company's products; risks relating
to the manufacturing capacity of third-party manufacturers for the Company's products, including risks of supply interruptions
impacting the Company's ability to manufacture its own products; risks relating to the Company's dependence on limited products
for substantially all of the Company's current revenues; risks relating to the Company's exposure to adverse movements in foreign
currency exchange rates; risks relating to the possibility that the Company could lose its foreign private issuer status under
U.S. federal securities laws; risks relating to breaches of anti-bribery laws by the Company's employees or agents; risks
associated with future changes in financial accounting standards and new accounting pronouncements; risks relating to the
Company's dependence upon key personnel to achieve its business objectives; the Company's ability to maintain strong
relationships with physicians; risks relating to the sufficiency of the Company's management systems and resources in periods of
significant growth; risks associated with consolidation in the health care industry, including the downward pressure on product
pricing and the growing need to be selected by larger customers in order to make sales to their members or participants; risks
relating to the Company's ability to successfully identify and complete corporate transactions on favorable terms or achieve
anticipated synergies relating to any acquisitions or alliances; risks relating to the Company's ability to successfully enter
into fundamental transactions as defined in the Series C warrants issued pursuant to the 2017 Financings; anti-takeover
provisions in the Company's constating documents which could discourage a third party from making a takeover bid beneficial to
the Company's shareholders; risks relating to conflicts of interests among the Company's officers and directors as a result of
their involvement with other issuers; and other factors referenced in the Company's filings with Canadian and U.S. securities
regulators. These risk factors and others relating to the Company are discussed in greater detail in the "Risk Factors" section
of the Company's Annual Report on Form 20-F and in Management's Discussion and Analysis for the quarter ended March 31, 2018 (copies of which may be obtained at www.sedar.com or www.sec.gov). The Company has no
intention and undertakes no obligation to update or revise any forward-looking statements beyond required periodic filings with
securities regulators, whether as a result of new information, future events or otherwise, except as required by law.
View original content:http://www.prnewswire.com/news-releases/neovasc-announces-publication-of-safety-and-efficacy-results-from-reduce-study-in-international-journal-of-cardiology-300692132.html
SOURCE Neovasc Inc.
View original content: http://www.newswire.ca/en/releases/archive/August2018/06/c2079.html